Antibiotic resistance problems with Helicobacter pylori

被引:110
作者
Alarcón, T [1 ]
Domingo, D [1 ]
López-Brea, M [1 ]
机构
[1] Hosp Univ Princesa, Dept Clin Microbiol, Madrid 28006, Spain
关键词
Helicobacter pylori; metronidazole; clarithromycin; resistance; susceptibility methods;
D O I
10.1016/S0924-8579(99)00051-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Helicobacter pylori is very susceptible in vitro to most antibiotics, but when they are used in the clinical setting, eradication of the bacteria from the gastric mucosa is not obtained. Dual or triple therapy including two of the following antibiotics: amoxicillin, tetracycline, metronidazole or clarithromycin, plus a proton pump inhibitor, bismuth salt or ranitidine bismuth citrate is the most frequently used. Various in vitro susceptibility methods have been used: disk diffusion, agar dilution and Epsilometer test (E-test). Metronidazole resistance among H. pylori strains is now found worldwide, and resistance rates vary according to the population studied. It is higher in developing than in developed countries and it could reach 80-90% in Africa. The prevalence on clarithromycin resistance is much lower, usually below 10%, although very high values are reported in Peru. Infection with metronidazole- or clarithromycin-resistant H. pylori strains is correlated with treatment failure when using regimens including these antibiotics. (C) 1999 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:19 / 26
页数:8
相关论文
共 93 条
  • [81] van Zwet AA, 1998, GUT, V43, pA6
  • [82] Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands
    vanderWouden, EJ
    vanZwet, AA
    Thijs, JC
    Vosmaer, GDC
    Oom, JAJ
    deJong, A
    Kleibeuker, JH
    [J]. EMERGING INFECTIOUS DISEASES, 1997, 3 (03) : 385 - 389
  • [83] Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk Agar in a miniwell format
    Vasquez, A
    Valdez, Y
    Gilman, RH
    McDonald, JJ
    Westblom, TU
    Berg, D
    Mayta, H
    Gutierrez, V
    Berendson, R
    LeonBarua, R
    RamirezRamos, A
    RecavarrenArce, S
    Watanabe, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (05) : 1232 - 1234
  • [84] Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance
    Versalovic, J
    Osato, MS
    Spakovsky, K
    Dore, MP
    Reddy, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) : 283 - 286
  • [85] Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori
    Versalovic, J
    Shortridge, D
    Kibler, K
    Griffy, MV
    Beyer, J
    Flamm, RK
    Tanaka, SK
    Graham, DY
    Go, MF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) : 477 - 480
  • [86] METRONIDAZOLE SUSCEPTIBILITY TESTING OF HELICOBACTER-PYLORI WITH THE PDM EPSILOMETER TEST (E-TEST)
    VONRECKLINGHAUSEN, G
    ANSORG, R
    [J]. ZENTRALBLATT FUR BAKTERIOLOGIE-INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY VIROLOGY PARASITOLOGY AND INFECTIOUS DISEASES, 1995, 282 (01): : 83 - 85
  • [87] TRANSFORMATION OF HELICOBACTER-PYLORI BY CHROMOSOMAL METRONIDAZOLE RESISTANCE AND BY A PLASMID WITH A SELECTABLE CHLORAMPHENICOL RESISTANCE MARKER
    WANG, Y
    ROOS, KP
    TAYLOR, DE
    [J]. JOURNAL OF GENERAL MICROBIOLOGY, 1993, 139 : 2485 - 2493
  • [88] WESTBLOM TU, 1992, J INFECT DIS, V165, P974
  • [89] HELICOBACTER-PYLORI-ASSOCIATED GASTRITIS AND PRIMARY B-CELL GASTRIC LYMPHOMA
    WOTHERSPOON, AC
    ORTIZHIDALGO, C
    FALZON, MR
    ISAACSON, PG
    [J]. LANCET, 1991, 338 (8776) : 1175 - 1176
  • [90] Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer
    Wurzer, H
    Rodrigo, L
    Stamler, D
    Archambault, A
    Rokkas, T
    Skandalis, N
    Fedorak, R
    Bazzoli, F
    Hentschel, E
    Mora, P
    Archimandritis, A
    Megraud, F
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) : 943 - 952